Broadly Protective Porcine Streptococcus suis Vaccines

Toward efficacious porcine Streptococcus suisvaccines for use globally in the feasibility SBIRPhase I component we demonstrated proof-of-concept for cross-protection engendered by amultivalent subunit vaccine (vaccine) constituted by a panel of immunologically conserved S. suisproteins (CPs) fromdisparate clinically relevant serotypes. Specifically we showed that pCPsfrom across 15 different serotypes identified using high-affinity antibodies against recombinantproteome of serotype 2 protected pigs against a heterologous challenge with wild type S. suisSerotype 3.In this SBIR Phase II study we propose to build on results of the Phase I componentvia studies to further vaccine efficacy and determine the potential of the vaccine developed in phaseI to protect against 15 diverse serotypes predominantly implicated in causation of porcine S. suisdisease globally. Phase II studies will be performed in collaboration with two Ames IA-basedentities: Veterinary Resources Inc. a veterinary CRO that performs livestock vaccine studies forentities across the United Sates; and ARKO labs a well-established veterinary vaccines entity witha track record of development and commercialization of livestock vaccines. An economical andefficacious vaccine capable of conferring robust cross protection will be both attractive to pigfarmers and significantly reduce economic losses to pork producers across North America /globally.The vaccine will also positively impact public health by decreasing incidence of humaninfection / disease caused by this emerging zoonotic pathogen.